Indivior Pharmaceuticals Inc logo INDV - Indivior Pharmaceuticals Inc

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 3
HOLD 0
SELL 0
STRONG
SELL 0
| PRICE TARGET: $44.67 DETAILS
HIGH: $50.00
LOW: $36.00
MEDIAN: $48.00
CONSENSUS: $44.67
UPSIDE: 19.02%
Annual Quarterly
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016
Revenue
Revenue 1,239 1,188 1,093 901 791 647 785 959.9 1,148.1 968.9
Cost of Revenue 246 231 174 151 127 97 140 134.7 122.9 110.8
Gross Profit 993 957 919 750 664 550 645 825.2 1,025.2 858.1
Operating Expenses
R&D Expenses 97 107 116 74 52 40 53 64.0 93.5 109.0
SG&A Expenses 634 618 569 469 431 649 395 444.1 508.4 411.2
Other Expenses (3) 200 390 288 (32) 17 19 0 0 0
Operating Expenses 728 925 1,075 831 451 706 467 508.1 601.9 520.2
Operating Income
Operating Income 265 32 (156) (81) 213 (156) 178 317.1 423.3 337.9
Interest Expense 45 41 35 29 26 24 22 31 49 51
Interest Income 22 23 43 19 4 7 24 17 7 0
Profitability
EBITDA 304 84 (99) (46) 238 (123) 230 310.4 437.0 149.3
EBIT 284 55 (114) (62) 216 (149) 202 295.1 193 136.4
Income Before Tax 239 14 (149) (89) 190 (173) 180 265.5 143.9 89.7
Income Tax Expense 29 11 (20) (44) (15) (25) 46 2.9 83.0 57.7
Net Income 210 2 (129) (44) 205 (148) 134 262.7 60.9 32.1
Per Share Data
EPS (Basic) 1.68 0.02 0.01 -0.37 1.38 -1.08 0.95 1.81 0.42 0.22
EPS (Diluted) 1.64 0.01 0.01 -0.37 1.31 -1.08 0.92 1.75 0.41 0.22
Shares Outstanding 125 132 137.3 139.0 145.7 146.6 146.0 145.4 144.2 144.0
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016
Current Assets
Cash & Cash Equivalents 195 319 316 778.2 1,102 858 1,060 924.0 863.0 692.0
Short-Term Investments 0 1 94 119.6 0 0 0 0 0 0
Net Receivables 255 254 254 220 202 219 204 278 257 205
Inventory 153 178 135 114.6 95 93 73 78.0 52.0 41.0
Other Current Assets 15 87 444 18 27 0 0 49.0 38 40
Total Current Assets 652 839 1,266 1,265.8 1,444 1,187 1,360 1,329.0 1,225.0 990.0
Non-Current Assets
Property, Plant & Equipment 170 139 124 85.5 95 103 107 57.0 54.0 27.0
Goodwill 0 2 0 0 0 0 0 0 0 0
Intangible Assets 2 5 13 70 82 62 72 0 0 0
Long-Term Investments 28 26 41 98.5 0 0 0 33.0 15.0 0
Other Non-Current Assets 26 29 28 38.6 106 104 73 84.0 92.0 83.0
Total Non-Current Assets 552 481 499 512.8 388 344 292 218.0 219.0 219.0
Total Assets 1,204 1,319 1,765 1,778.6 1,832 1,531 1,652 1,547.0 1,444.0 1,209.0
Current Liabilities
Account Payables 48 63 39 33 26 416 499 47 40 33
Short-Term Debt 39 18 12 3 3 12 9 4 5 101
Deferred Revenue 0 0 0 9.0 0 0 0 24.0 41.0 52.0
Other Current Liabilities 722 802 1,159 391 635 156 195 603.0 617.0 673
Total Current Liabilities 914 939 1,290 1,024.5 804 599 742 818.0 854.0 1,030.0
Non-Current Liabilities
Long-Term Debt 290 315 237 237 239 230 233 237 477 434
Deferred Tax Liabilities 3 0 5 0 0 0 0 0 0 0
Other Non-Current Liabilities 73 381 390 436.8 550 577 417 426.0 316.0 40.0
Total Non-Current Liabilities 388 728 666 702.8 825 850 701 663.0 793.0 474.0
Total Liabilities 1,302 1,667 1,956 1,727.3 1,629 1,449 1,443 1,481.0 1,647.0 1,504.0
Stockholders' Equity
Common Stock 62 62 68 68.4 70 73 73 73.0 72.0 72.0
Retained Earnings (243) (454) (295) 1,310.0 1,438 1,311 1,449 1,315.0 1,032.0 950.0
Accumulated Other Comprehensive Income (30) (46) (1,348) (1,335.2) 0 (1,308) (1,318) (1,327.0) (1,309.0) (1,317.0)
Total Stockholders' Equity (98) (348) (191) 51.3 203 82 209 66.0 (203.0) (295.0)
Total Liabilities & Equity 1,204 1,319 1,765 1,778.6 1,832 1,531 1,652 1,547.0 1,444.0 1,209.0
Debt Metrics
Total Debt 351 375 283 277 286 285 293 241.0 482.0 535.0
Net Debt 156 56 (33) (501.2) (816) (573) (767) (683.0) (381.0) (157.0)
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016
Operating Activities
Net Income 210 2 (129) (44) 213 (156) 178 262.7 60.9 32.1
Depreciation & Amortization 20 29 15 16 22 26 28 15.3 13.7 12.8
Stock-Based Compensation 26 24 21 16 11 8 3 0 0 0
Change in Working Capital (257) (41) (294) 118 173 (19) (79) 27.7 148.1 309.5
Other Non-Cash Items 20 16 87 (110) (66) (52) 21 20.1 177.5 (65.0)
Operating Cash Flow (27) 36 (300) (4) 353 (193) 151 289.4 309.9 372.7
Investing Activities
Capital Expenditure (66) (29) (53) (5) (34) (4) (7) (39.2) (45.2) (32.1)
Acquisitions 0 0 (129) 0 0 0 0 0 0 0
Purchases of Investments (20) (17) (45) (245) 0 0 0 0 0 0
Sales/Maturities of Investments 0 117 129 27 0 0 0 0 0 0
Other Investing Activities 20 (2) (42) 1 (10) 0 5 35.3 0 0
Investing Cash Flow (66) 69 (95) (222) (14) (4) (2) (3.8) (45.2) (32.1)
Financing Activities
Net Debt Issuance (17) 92 (12) (3) 14 (4) (4) (229.2) (86) (78)
Stock Repurchased (11) (173) (33) (90) (101) 0 0 0 0 0
Dividends Paid 0 0 0 0 0 0 0 0 0 (63.2)
Other Financing Activities (4) (24) (22) (10) (8) (7) (9) (10.8) 0 12.4
Financing Cash Flow (30) (102) (64) (101) (94) (10) (13) (226.4) (88.2) (134.6)
Cash Position
Net Change in Cash (124) 3 (458) (328) 244 (202) 136 61.0 171.0 206.0
Cash at Beginning 319 316 774 1,102 858 1,060 924 863.0 692.0 486.0
Cash at End 195 319 316 774 1,102 858 1,060 924.0 863.0 692.0
Free Cash Flow (93) 7 (353) (9) 319 (197) 144 250.2 264.7 340.7
Key Metrics 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016
Income Statement
Revenue 1,239 1,188 1,093 901 791 647 785 959.9 1,148.1 968.9
Gross Profit 993 957 919 750 664 550 645 825.2 1,025.2 858.1
Operating Income 265 32 (156) (81) 213 (156) 178 317.1 423.3 337.9
Net Income 210 2 (129) (44) 205 (148) 134 262.7 60.9 32.1
EPS (Diluted) 1.64 0.01 0.01 -0.37 1.31 -1.08 0.92 1.75 0.41 0.22
Balance Sheet
Cash & Equivalents 195 319 316 778.2 1,102 858 1,060 924.0 863.0 692.0
Total Assets 1,204 1,319 1,765 1,778.6 1,832 1,531 1,652 1,547.0 1,444.0 1,209.0
Total Debt 351 375 283 277 286 285 293 241.0 482.0 535.0
Stockholders' Equity (98) (348) (191) 51.3 203 82 209 66.0 (203.0) (295.0)
Cash Flow
Operating Cash Flow (27) 36 (300) (4) 353 (193) 151 289.4 309.9 372.7
Capital Expenditure (66) (29) (53) (5) (34) (4) (7) (39.2) (45.2) (32.1)
Free Cash Flow (93) 7 (353) (9) 319 (197) 144 250.2 264.7 340.7